Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™

Read More

Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

Read More

Ligand to Participate in the Stephens 2019 Nashville Investment Conference

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range